Back to top
more

Dynavax Technologies (DVAX)

(Real Time Quote from BATS)

$10.97 USD

10.97
759,701

-0.22 (-1.97%)

Updated Sep 11, 2024 01:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ekta Bagri headshot

Bet on These 4 Biotech Stocks With Bright Prospects

by Ekta Bagri

New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.

Atea (AVIR) Dengue Candidate Gets Fast Track Designation

by Zacks Equity Research

Atea Pharmaceuticals (AVIR) obtains Fast Track Designation in the United States for AT-752 for the treatment of dengue virus infection.

Dynavax Technologies (DVAX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Dynavax Technologies (DVAX) closed the most recent trading day at $10.24, moving +1.69% from the previous trading session.

Gilead (GILD) Drugs Get Positive CHMP Opinion for Label Expansion

by Zacks Equity Research

Gilead's (GILD) COVID-19 treatment Veklury and CAR T-cell therapy Yescarta get positive CHMP recommendation for additional indications.

Bristol Myers (BMY) Skin Cancer Drug Gets EC's Approval

by Zacks Equity Research

Bristol Myers (BMY) gets EC approval for the fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor Opdivo (nivolumab and novel LAG-3-blocking antibody relatlimab.

WHO Recommends Gilead's (GILD) Veklury for Severe COVID-19

by Zacks Equity Research

Gilead's (GILD) Veklury is now recommended by the WHO for use in both non-severe COVID-19 patients at the highest risk of hospitalization and those with severe COVID-19.

Bristol Myers' (BMY) Opdivo Meets Main Goal in Melanoma Study

by Zacks Equity Research

Bristol Myers' (BMY) immuno-oncology drug Opdivo demonstrates a statistically significant and clinically meaningful improvement in recurrence-Free survival (RFS) in patients with Stage IIB/C melanoma.

Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study

by Zacks Equity Research

Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.

Is Dynavax Technologies (DVAX) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Gilead (GILD) Up on Settling HIV Drug Suit With Generic Players

by Zacks Equity Research

Gilead (GILD) enters settlement agreements with a few generic manufacturers to resolve the litigation and patent challenges associated with HIV treatments, such as Descovy, Vemlidy and Odefsey.

Edgewise (EWTX) Up 9.37% on Positive Data From BMD Study

by Zacks Equity Research

Edgewise (EWTX) stock gains on upbeat interim results from the ARCH study of its lead candidate EDG-5506 in adults with Becker Muscular Dystrophy (BMD).

Dynavax Technologies (DVAX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Dynavax Technologies (DVAX) closed at $11.78, marking a +1.12% move from the previous day.

Bristol Myers (BMY) Gets FDA Approval for Psoriasis Candidate

by Zacks Equity Research

Bristol Myers (BMY) secures an FDA nod for Sotyktu to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Regeneron (REGN) Up on Higher Dose Eye Drug Studies Success

by Zacks Equity Research

Regeneron (REGN) stock jumps as aflibercept 8 mg with 12- and 16-week dosing regimens in patients with DME and wAMD meet primary goals.

Exelixis (EXEL) Reports Positive Cabometyx Combo Study Results

by Zacks Equity Research

Exelixis (EXEL) announces positive detailed results on the triplet combination study of Cabometyx, Opdivo and Yervoy.

Gilead (GILD) Breast Cancer Drug Trodelvy Improves Survival

by Zacks Equity Research

Gilead (GILD) breast cancer drug Trodelvy demonstrates a statistically significant and clinically meaningful improvement of 3.2 months in overall survival compared to chemotherapy.

Spero (SPRO) Up Following Positive FDA Update for UTI Drug

by Zacks Equity Research

Spero (SPRO) surges on achieving common ground with the FDA on the regulatory path forward for tebipenem HBr.

Gilead (GILD) Announces Positive New Data on Breast Cancer Drug

by Zacks Equity Research

Gilead (GILD) breast cancer drug Trodelvy shows efficacy across HER2-low and IHC0 status in pre-treated metastatic breast cancer patients.

Jounce (JNCE) SELECT Study Fails to Meet Goal, Stock Down

by Zacks Equity Research

Jounce Therapeutics (JNCE) declines as its mid-stage study, SELECT, evaluating vopratelimab in lung cancer patients, fails to meet the primary endpoint.

Novartis (NVS) Chronic Myeloid Leukemia Drug Approved by EC

by Zacks Equity Research

Novartis (NVS) strengthens its oncology portfolio with EC approval for its chronic myeloid leukemia drug, Scemblix.

Gilead (GILD) Outpaces Industry in Six Months: What Lies Ahead?

by Zacks Equity Research

Gilead (GILD) gains on the back of its strong HIV franchise and promising oncology business, which should propel growth further.

Down 21.7% in 4 Weeks, Here's Why Dynavax Technologies (DVAX) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for Dynavax Technologies (DVAX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Bristol Myers (BMY) Announces Milvexian Phase II Study Results

by Zacks Equity Research

Bristol Myers (BMY) announces AXIOMATIC-SSP study results of milvexian, an investigational oral factor XIa inhibitor, for preventing new symptomatic ischemic stroke or new covert brain infarction.

Incyte (INCY) Gets FDA Nod for Label Expansion of Pemazyre

by Zacks Equity Research

Incyte (INCY) obtains FDA approval for Pemazyre for a second indication - the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Bristol Myers (BMY) Up 14.6% YTD: Will the Performance Continue?

by Zacks Equity Research

Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue on label expansion of existing drugs.